Close

NeoStem (NBS) Receives ATMP Classification for NBS20

April 27, 2015 7:34 AM EDT Send to a Friend
NeoStem (NASDAQ: NBS) announced that the European Medicines Agency (EMA) has classified the Company's lead immuno-oncology product candidate, NBS20, as ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login